Universe PharmaceuticalsUPC -8.85%62 3-Year ROIIC % is 1,298.42 as of Sep. 2025, which is 11922% above its 10-year median of 10.80. GuruFocus rates UPC with a GF Score™ of 62/100 and a GF Value™ of $5.21 (Fairly Valued). The stock has 9 warning signs investors should review. Among 942 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 98.51% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Universe Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was 1,298.42%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Universe Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
UPC's 3-Year ROIIC % is ranked better than 98.51% of 942
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs UPC: 1298.42
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Universe Pharmaceuticals 3-Year ROIIC % Related Terms
Universe Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs CPMD, SHPH, NPHC: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's 3-Year ROIIC % falls into.
Universe Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.916 (Sep. 2025) - -7.019 (Sep. 2022) )
/
( 31.835 (Sep. 2025) - 31.519 (Sep. 2022) )
=
4.103
/
0.316
=
1,298.42%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Universe Pharmaceuticals (UPC) has a 3-Year ROIIC % of 1,298.42 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Universe Pharmaceuticals and its competitors. This is 11922% above median its historical median of 10.80. According to the industry distribution chart, Universe Pharmaceuticals ranks #14 out of 942 companies in the Drug Manufacturers industry, placing it in the top 1.5%.
Is Universe Pharmaceuticals' 3-Year ROIIC % too high?
Universe Pharmaceuticals' current 3-Year ROIIC % of 1,298.42 is 11922% above median its 10-year median of 10.80. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Universe Pharmaceuticals' value of 1,298.42 is 34803.8% above this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #14 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' 3-Year ROIIC % compare to CPMD and SHPH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #14 out of 942 companies for 3-Year ROIIC %. This places Universe Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Universe Pharmaceuticals' value of 1,298.42 is 34803.8% above this benchmark. While the company's 10-year median is 10.80 vs. the industry median of 3.72, Universe Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current 3-Year ROIIC % of 1,298.42 is 34803.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current 3-Year ROIIC % is 1,298.42, which is 11922% above median its own 10-year median of 10.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Fairly Valued. The stock's GF Value™ is $5.21, compared to a current price of $5.56 — trading 6.7% above its estimated fair value. The current 3-Year ROIIC % is 1,298.42, which is 11922% above median its 10-year median of 10.80 and 34803.8% above the Drug Manufacturers industry median of 3.72. Universe Pharmaceuticals' overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current 3-Year ROIIC % is 1,298.42 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.56 is trading 6.7% above its estimated GF Value™ of $5.21.
GuruFocus considers Universe Pharmaceuticals to be Fairly Valued.
Key valuation signals for UPC:
3-Year ROIIC %: 1,298.42 (11922% above median its 10-year median of 10.80)
GF Value™: $5.21 vs. price of $5.56 (6.7% above fair value)
Industry Position: 34803.8% above the Drug Manufacturers median (#14 of 942)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
62GF Score
Get the complete analysis for UPC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
